13F Holdings
中文EN

NUVB Nuvation Bio Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1811063 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY654.2%
TTM net income YoY37.5%
TTM EPS YoY20.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-61.2%
Net margin-67.4%
FCF margin—
EBITDA margin-60.1%

Returns

ROE-49.1%
ROA-19.7%
ROIC (approx.)-30.5%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets70.7%
Debt / equity1.25x
Current ratio7.45x
Interest coverage-5.87x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$62.90M$7.87M$0——
Cost of revenue—$7.08M$0——
Gross profit—$795,000$0——
R&D expense$115.11M$99.12M$71.29M$87.81M$69.04M
SG&A expense$151.56M$69.23M$28.53M$31.92M$24.28M
Operating income-$213.06M-$592.63M-$99.82M-$119.73M-$93.32M
Interest expense$13.68M$341,000$0——
Pretax income-$204.63M-$567.94M-$75.80M-$104.20M-$86.85M
Income tax$0$0$0$0$0
Net income-$204.63M-$567.94M-$75.80M-$104.20M-$86.85M
EBITDA-$211.32M-$591.94M-$99.60M-$119.53M-$93.13M
EPS (basic)-0.60-2.11-0.35-0.48-0.44
EPS (diluted)-0.60-2.11-0.35-0.48-0.44
Weighted avg. shares (diluted)341,541268,772218,880216,721197,887
Balance sheet
Cash & equivalents$164.09M$35.72M$42.65M$101.10M$132.42M
Short-term investments$365.12M$466.97M$568.56M$559.91M$632.97M
Inventory$11.41M$0———
Current assets$571.52M$526.25M$616.43M$667.32M$772.07M
PP&E, net$564,000$586,000$717,000$894,000$786,000
Intangibles$11.21M$4.62M$0——
Total assets$594.82M$540.63M$621.48M$672.14M$776.15M
Current liabilities$82.23M$58.24M$13.97M$13.16M$16.93M
Short-term debt$5.72M$6.28M$0——
Long-term debt$47.21M————
Total debt$52.93M————
Total liabilities$289.11M$76.84M$16.36M$17.07M$30.15M
Shareholders' equity$305.72M$463.79M$605.12M$655.08M$746.00M
Net debt-$111.15M————
Shares outstanding346.50M337.84M219.05M218.63M217.95M
Cash flow statement
Operating cash flow-$173.43M-$130.41M-$68.00M-$96.11M-$68.19M
Capital expenditure$8.00M$0———
Free cash flow-$181.43M-$130.41M———
Investing cash flow$99.52M$122.70M$8.92M$63.46M-$454.67M
Financing cash flow$202.53M$331,000$628,000$1.33M$625.53M
Depreciation & amortization$1.74M$683,000$222,000$199,000$184,000
Stock-based compensation$35.89M$32.27M$19.51M$16.29M$9.27M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.